2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗

2019-04-15 欧洲卒中组织 European Stroke Journal.2019.1–26.

2019年4月,欧洲卒中组织(ESO)发布了卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗指南,文章主要建议内容涉及药物治疗时间和桥接治疗,左心房封堵术,既往脑出血患者重新开始治疗,特定患者的药物治疗等。

中文标题:

2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗

英文标题:

Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline

发布机构:

欧洲卒中组织

发布日期:

2019-04-15

简要介绍:

2019年4月,欧洲卒中组织(ESO)发布了卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗指南,文章主要建议内容涉及药物治疗时间和桥接治疗,左心房封堵术,既往脑出血患者重新开始治疗,特定患者的药物治疗等。 

拓展指南:卒中相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗)] GetToolGuiderByIdResponse(projectId=1, id=80f951c001e3a562, title=2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗, enTitle=Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline, guiderFrom=European Stroke Journal.2019.1–26., authorId=null, author=, summary=2019年4月,欧洲卒中组织(ESO)发布了卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗指南,文章主要建议内容涉及药物治疗时间和桥接治疗,左心房封堵术,既往脑出血患者重新开始治疗,特定患者的药物治疗等。 , cover=, journalId=null, articlesId=null, associationId=277, associationName=欧洲卒中组织, associationIntro=欧洲卒中组织成立于2007年12月,是关于卒中的研究协会,由两个相关协会:欧洲卒中会议( European Stroke Council,ESC)和欧洲卒中促进会(European Stroke Initiative ,EUSI)组成,旨在通过改变卒中的看待和处理方式,来减少卒中的发病率和影响。该组织提供最佳临床实践方法,以协调欧洲的卒中管理。, copyright=0, guiderPublishedTime=Mon Apr 15 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年4月,欧洲卒中组织(ESO)发布了卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗指南,文章主要建议内容涉及药物治疗时间和桥接治疗,左心房封堵术,既往脑出血患者重新开始治疗,特定患者的药物治疗等。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>卒中</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=707da1c001e3378f" title="2019 韩国临床实践指南:急性缺血性卒中患者血管内再通治疗" target=_blank>2019 韩国临床实践指南:急性缺血性卒中患者血管内再通治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c26251c001e16916" title="2019 澳大利亚临床指南:儿童卒中亚急性康复" target=_blank>2019 澳大利亚临床指南:儿童卒中亚急性康复</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f24921c001e122b4" title="2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术" target=_blank>2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=406f51c001e11618" title="“移动卒中单元”中国专家共识2019" target=_blank>“移动卒中单元”中国专家共识2019</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=59c071c0016981c0" title="2019 AHA/ASA科学声明:新生儿和儿童卒中的管理" target=_blank>2019 AHA/ASA科学声明:新生儿和儿童卒中的管理</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%8D%92%E4%B8%AD" target=_blank>有关卒中更多指南</a></ul>, tagList=[TagDto(tagId=365, tagName=卒中), TagDto(tagId=3482, tagName=短暂性脑缺血发作), TagDto(tagId=5745, tagName=非瓣膜性房颤), TagDto(tagId=3552, tagName=二级预防), TagDto(tagId=3301, tagName=抗栓治疗)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13625, appHits=739, showAppHits=9, pcHits=8419, showPcHits=5752, likes=124, shares=29, comments=8, approvalStatus=1, publishedTime=Mon May 06 23:02:41 CST 2019, publishedTimeString=2019-04-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon May 06 23:02:41 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 13:26:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗)])
2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1058360, encodeId=a3d6105836066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Thu Oct 07 14:35:29 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925685, encodeId=926492568529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925684, encodeId=a780925684c7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:48:54 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901304, encodeId=143d901304cc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:25 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899967, encodeId=627889996e96, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:39 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2021-10-07 老龙一点

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1058360, encodeId=a3d6105836066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Thu Oct 07 14:35:29 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925685, encodeId=926492568529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925684, encodeId=a780925684c7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:48:54 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901304, encodeId=143d901304cc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:25 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899967, encodeId=627889996e96, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:39 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2021-02-20 1257d324m68暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1058360, encodeId=a3d6105836066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Thu Oct 07 14:35:29 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925685, encodeId=926492568529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925684, encodeId=a780925684c7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:48:54 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901304, encodeId=143d901304cc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:25 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899967, encodeId=627889996e96, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:39 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2021-02-20 1257d324m68暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1058360, encodeId=a3d6105836066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Thu Oct 07 14:35:29 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925685, encodeId=926492568529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925684, encodeId=a780925684c7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:48:54 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901304, encodeId=143d901304cc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:25 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899967, encodeId=627889996e96, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:39 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2020-11-22 911524993

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1058360, encodeId=a3d6105836066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Thu Oct 07 14:35:29 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925685, encodeId=926492568529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925684, encodeId=a780925684c7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:48:54 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901304, encodeId=143d901304cc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:25 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899967, encodeId=627889996e96, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:39 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2020-11-17 120cac51m28暂无昵称

    0